Cytomedix, Inc.  

(Public, OTCMKTS:CMXI)   Watch this stock  
Find more results for OTC:CMXI
0.429
-0.026 (-5.71%)
Sep 16 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.40 - 0.45
52 week 0.33 - 0.68
Open 0.45
Vol / Avg. 979,748.00/386,860.00
Mkt cap 58.57M
P/E     -
Div/yield     -
EPS -0.24
Shares 124.41M
Beta -0.71
Inst. own 3%
Sep 9, 2014
Cytomedix Inc at Rodman & Renshaw Global Investment Conference
  

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -486.68% -174.99%
Operating margin -422.27% -156.38%
EBITD margin - -133.44%
Return on average assets -78.58% -44.71%
Return on average equity -218.05% -62.48%
Employees 40 -
CDP Score - -

Address

SUITE 7, 209 PERRY PARKWAY
GAITHERSBURG, MD 20877
United States - Map
+1-240-4992680 (Phone)
+1-240-4992690 (Fax)

Website links

Description

Cytomedix, Inc. (Cytomedix) is a regenerative therapies company marketing and developing products within the United States and internationally .The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company is a commercial operation, and a robust clinical pipeline representing a logical extension of its commercial technologies in the evolving field of regenerative medicine. Cytomedix primarily operates in the United States. Its commercial offerings are centered on its point of care platform technologies for the safe and efficient separation of blood and bone marrow to produce platelet based therapies or cell concentrates. In February 2012, the Company acquired Aldagen, Inc.

Officers and directors

David Emerson Jorden CPA Executive Chairman of the Board
Age: 51
Martin P. Rosendale Chief Executive Officer, Director
Age: 56
Steven S. Shallcross CPA Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 52
Peter A. Clausen Ph.D. Chief Science Officer
Dean Tozer Chief Commercial Officer
Lyle A. Hohnke Ph.D. Director
Age: 70
Joseph Del Guercio Independent Director
Age: 41
Stephen N. Keith M.D. Independent Director
Richard S. Kent M.D. Independent Director
Age: 64
Mark T. McLoughlin Independent Director
Age: 58